Pesquisas alternativas:
"dao open" » "ao open" (Expandir a Pesquisa), "caso open" (Expandir a Pesquisa), "two open" (Expandir a Pesquisa), "daao open" (Expandir a Pesquisa), "dao opens" (Expandir a Pesquisa), "da1 open" (Expandir a Pesquisa)
"so open" » "ao open" (Expandir a Pesquisa), "caso open" (Expandir a Pesquisa), "two open" (Expandir a Pesquisa), "sao open" (Expandir a Pesquisa), "so opens" (Expandir a Pesquisa), "s1 open" (Expandir a Pesquisa)
"do open" » "two open" (Expandir a Pesquisa), "oto open" (Expandir a Pesquisa), "dao open" (Expandir a Pesquisa), "do opens" (Expandir a Pesquisa), "d1 open" (Expandir a Pesquisa)
"esmo open" » "esmao open" (Expandir a Pesquisa), "esmo opens" (Expandir a Pesquisa), "esm1 open" (Expandir a Pesquisa), "esto open" (Expandir a Pesquisa), "eso open" (Expandir a Pesquisa), "ecmo open" (Expandir a Pesquisa)
"o open" » "ao open" (Expandir a Pesquisa), "o opens" (Expandir a Pesquisa), "1 open" (Expandir a Pesquisa)
A mostrar 1 - 20 resultados de 1,029 para a pesquisa '(("esmo open") OR ((((("so open") OR ("do open"))) OR ((("o open") OR ("dao open"))))))', tempo de pesquisa: 3.87seg Refinar resultados
AIOM chooses ESMO Open—Cancer Horizons as its official journal: a warm welcome from ESMO Open
ESMO Open—Cancer Horizons and the future of oncology

CSCO joins ESMO Open—Cancer Horizons
ESMO Open: news in breast cancer 2019

ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO)
ESMO Open special series on new emerging targets in cancer immunotherapy

Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment
One year of ESMO Open: Cancer Horizons—where are we going from here?

Plasmodesmata. A Not So Open-and-Shut Case
Introducing a new ESMO Open article series: how I treat side effects of immunotherapy

Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open–Cancer Horizons roundtable discussion
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open—Cancer Horizons pro and con discussion
Desafios do Open Design

New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an “ESMO Open – Cancer Horizons” Series
Erratum to ‘FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?’: [ESMO Open Volume 5, Issue 5, 2020, e000633]

Adoção do Open Peer Review
How do Openers Contribute to Student Learning?

Criptografia digital: implementação do OpenPGP
Erratum to ‘Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis’: [ESMO Open Volume 6, Issue 2, April 2021, 100088]

Ferramentas de pesquisa: Obter Feed RSS — Enviar pesquisa por email — Guardar a pesquisa